 |
 Video: Compound Annual Growth Rate (CAGR) Definition
|
|
| Date |
Open |
High |
Low |
Close |
Volume |
| 04/15/2024 |
$51.76 |
$53.04 |
$50.28 |
$51.50 |
2.62M | | 04/16/2024 |
$51.40 |
$53.06 |
$50.70 |
$51.82 |
1.01M | | 04/17/2024 |
$51.67 |
$52.44 |
$47.96 |
$48.03 |
1.68M | | 04/18/2024 |
$47.91 |
$48.83 |
$46.40 |
$47.51 |
1.95M | | 04/19/2024 |
$47.52 |
$48.19 |
$46.53 |
$47.53 |
1.18M |
|
|
| Apellis Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutic compounds to treat diseases through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Pegcetacoplan targets C3, the central protein of the complement cascade. Pegcetacoplan is a conjugate of a compstatin analogue, formulated both for intravitreal administration by injections directly into the eye, and systemic administration by subcutaneous injection, which is an injection into the tissue under the skin. | |
|
Apellis Pharmaceuticals (APLS) has the following price history information. Looking back at APLS historical stock prices for the last five trading days, on April 15, 2024, APLS opened at $51.76, traded as high as $53.04 and as low as $50.28, and closed at $51.50. Trading volume was a total of 2.62M shares. On April 16, 2024, APLS opened at $51.40, traded as high as $53.06 and as low as $50.70, and closed at $51.82. Trading volume was a total of 1.01M shares. On April 17, 2024, APLS opened at $51.67, traded as high as $52.44 and as low as $47.96, and closed at $48.03. Trading volume was a total of 1.68M shares. On April 18, 2024, APLS opened at $47.91, traded as high as $48.83 and as low as $46.40, and closed at $47.51. Trading volume was a total of 1.95M shares. On April 19, 2024, APLS opened at $47.52, traded as high as $48.19 and as low as $46.53, and closed at $47.53. Trading volume was a total of 1.18M shares.
APLS Historical Stock Prices By Date:
Below, we examine the compound annual growth rate — CAGR for short — of an investment into Apellis Pharmaceuticals shares, starting with a $10,000 purchase of APLS, and working forward through the historical stock price information to today.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
11/10/2017 |
|
| End date: |
04/19/2024 |
|
| Start price/share: |
$14.00 |
|
| End price/share: |
$47.53 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
239.50% |
|
| Average Annual Total Return: |
20.90% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$33,955.94 |
|
| Years: |
6.44 |
|
|
|
| Date |
Close |
| 04/15/2024 | $51.50 | | 04/16/2024 | $51.82 | | 04/17/2024 | $48.03 | | 04/18/2024 | $47.51 | | 04/19/2024 | $47.53 |
|
|
Free APLS Email Alerts:
